These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 301777)

  • 41. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: intervention of folic and folinic acid.
    Padmanabhan S; Tripathi DN; Vikram A; Ramarao P; Jena GB
    Mutat Res; 2009 Feb; 673(1):43-52. PubMed ID: 19110071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration.
    Studenberg SD; Woolley JL; Deangelis DV; Wargin WA
    Biopharm Drug Dispos; 1997 Jul; 18(5):433-42. PubMed ID: 9210981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kinetics of metoprine, a lipid-soluble antifolate.
    Jones BR; Gordon CS; Umans J; Reidenberg MM; Young CW
    Br J Clin Pharmacol; 1981 Nov; 12(5):675-80. PubMed ID: 7332733
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The intracellular mechanism of action of metoprine (DDMP).
    Browman GP; Calvert AH; Taylor GA; Hart LI; Harrap KR
    Eur J Cancer (1965); 1980 Dec; 16(12):1547-54. PubMed ID: 6971755
    [No Abstract]   [Full Text] [Related]  

  • 45. Uptake, cytotoxicity and metabolism of m-azidopyrimethamine and related lipophilic antifolates in SV-K14 human keratinocytes in vivo.
    Baker ND; Griffin RJ; Irwin WJ; Reichert U; Schmidt R
    Biochem Pharmacol; 1991 Dec; 42 Suppl():S39-46. PubMed ID: 1768284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics: selectivity of action related to physicochemical properties and kinetic patterns of anticancer drugs.
    Nichol CA
    Cancer; 1977 Jul; 40(1 Suppl):519-28. PubMed ID: 328135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I clinical trial and pharmacology of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (metoprine) (DDMP) and folinic acid (CF).
    de Jager R; Dupont D; Rodzynek JJ; Dorlet C; Lagrange G
    Cancer Chemother Pharmacol; 1981; 6(1):75-80. PubMed ID: 6974058
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of calcium folinate in the management of accidental methotrexate ingestion in two dogs.
    Lewis DH; Barfield DM; Humm KR; Goggs RA
    J Am Vet Med Assoc; 2010 Dec; 237(12):1450-4. PubMed ID: 21155685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Initial clinical studies of piritrexim.
    Laszlo J; Brenckman WD; Morgan E; Clendeninn NJ; Williams T; Currie V; Young C
    NCI Monogr; 1987; (5):121-5. PubMed ID: 3323908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the antitumor activity and toxicity of 2,4-diamino-5-(1-adamantyl)-6-methylpyrimidine and 2,4-diamino-5-(1-adamantyl)-6-ethylpyrimidine.
    Zakrzewski SF; Dave C; Rosen F
    J Natl Cancer Inst; 1978 May; 60(5):1029-33. PubMed ID: 580441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Formulation of de novo substituent constants in correlation analysis: inhibition of dihydrofolate reductase by 2,4-diamino-5-(3,4-dichlorophenyl)-6-substituted pyrimidines.
    Hansch C; Silipo C; Steller EE
    J Pharm Sci; 1975 Jul; 64(7):1186-91. PubMed ID: 1151681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of folic or folinic acid on the toxicity of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3,4-dichlorobenzyloxy)-1,3,5-triazine hydrochloride, an antifolate, in dogs.
    Lee CC; Heiffer MH; Kintner LD
    Toxicol Appl Pharmacol; 1976 Oct; 38(1):29-37. PubMed ID: 1086534
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase II clinical trial of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine) and folinic acid (CF) in solid tumors.
    de Jager R; Brugarolas A; Hansen M
    Cancer Chemother Pharmacol; 1981; 6(1):81-4. PubMed ID: 6974059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methotrexate resistance and uptake of DDMP by L5178Y cells. Selective protection with folinic acid.
    Hill BT; Price LA; Goldie JH; Harrison SI
    Eur J Cancer (1965); 1975 Aug; 11(8):545-53. PubMed ID: 1083340
    [No Abstract]   [Full Text] [Related]  

  • 55. Inhibition by pyrimidine analogues of the synthesis of folic acid by trachoma agents.
    Reeve P; Taverne J; Bushby SR
    J Hyg (Lond); 1968 Jun; 66(2):295-306. PubMed ID: 5304542
    [No Abstract]   [Full Text] [Related]  

  • 56. Quantitative thin-layer chromatography of pyrimethamine and related diaminopyrimidines in body fluids and tissues.
    DeAngelis RL; Simmons WS; Nichol CA
    J Chromatogr; 1975 Mar; 106(1):41-9. PubMed ID: 168216
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of certain 2,4-diaminopyrimidine antagonists of folic acid on pregnancy and rat fetus.
    THIERSCH JB
    Proc Soc Exp Biol Med; 1954 Dec; 87(3):571-7. PubMed ID: 13237310
    [No Abstract]   [Full Text] [Related]  

  • 58. Quantitative high-pressure liquid chromatographic procedure for the determination of plasma and tissue levels of 2,4-diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine (metoprine) and its application to the measurement of brain capillary permeability coefficients.
    Levin EM; Meyer RB; Levin VA
    J Chromatogr; 1978 Aug; 156(1):181-7. PubMed ID: 689956
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new class of cytostatic folic acid antagonists 1-(3,4-dichlorophenyl)-5-isopropyl-biguanide and its boron compounds.
    Bollag W
    Experientia; 1968 Oct; 24(10):1049-50. PubMed ID: 5304711
    [No Abstract]   [Full Text] [Related]  

  • 60. Irreversible enzyme inhibitors. CLXVI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 2,4-diamino-5(3,4-dichlorophenyl)pyrimidine with 6 substituents and some factors in their cell wall transport.
    Baker BR; Vermeulen NM
    J Med Chem; 1970 Jan; 13(1):82-6. PubMed ID: 5460895
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.